

ANGOLA

Support for Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Angola			
2. Grant number: 1518-AGO-25c-X			
3. Date of Decision Letter: 27 February 2017			
4. Date of the Partnership Framework Agreement: 04 October 2013			
5. Programme title: New Vaccine Support (NVS), IPV routine			
6. Vaccine type: Inactivated Polio Vaccine (IPV)			
7. Requested product presentation and formulation of vaccine¹: Inactivated Polio Vaccine, 10 doses per vial, LIQUID			
8. Programme duration²: 2015 – 2018			
9. Programme Budget (indicative): <i>Please note that endorsed or approved amounts for 2018 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i>			
	2015-2016	2017	Total³
Programme Budget (US\$)	129,053	332,500	461,553
10. Vaccine introduction grant: \$785,500 was disbursed on 6 July 2015 as per the decision letter dated 4 February 2015			
11. Indicative Annual Amounts:⁴			
Type of supplies to be purchased with Gavi funds in each year			2017
Number of IPV vaccines doses			371,100
Annual Amounts (US\$)			332,500
12. Procurement agency: UNICEF			

¹ Please refer to section 18 for additional information on IPV presentation.

² This is the entire duration of the Programme.


³ This is the total amount endorsed by Gavi for 2015 to 2017.

⁴ This is the amount that Gavi has approved.

13. Self-procurement: Not applicable	
14. Co-financing obligations: Not applicable Gavi's usual co-financing requirements do not apply to IPV. However, Angola is encouraged to contribute to vaccine and/or supply costs for IPV.	
15. Operational support for campaigns: Not applicable	
16. Additional reporting requirements:	
Reports and other information	Due dates
Angola shall submit the following information in May: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2017
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
17. Financial clarifications: Not applicable	
18. Other conditions:	
<p>Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply is highly constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual number of doses shipped may differ from the amounts specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.</p> <p>If Angola envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Angola.</p>	

On behalf of Gavi

Signed by



Hind Khatib-Othman
Managing Director, Country Programmes
27 February 2017